Bayer chief executive Bill Anderson has followed through on a pledge to streamline the group’s management, starting at the very top with a big reduction in the pharma unit
Bayer chief executive Bill Anderson pulled no punches in his assessment of the company at its annual results update, saying it is “badly broken” by patent losses, litigati
After lengthy negotiations, Bayer has reached a deal with union representatives that will result in a sizeable reduction in managerial roles, part of a cost-cutting drive
One of Germany’s main trade unions has pushed back against any future break-up of pharmaceutical and agrochemicals giant Bayer, claiming such a move would put thousands of
Bayer’s new chief executive Bill Anderson has launched a “re-design” of Bayer that will see layers of management stripped out by the end of next year, with “95% of the dec
AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.